<DOC>
	<DOCNO>NCT00003819</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . PURPOSE : Phase I trial study effectiveness vaccine therapy give QS21 treat patient progressive prostate cancer .</brief_summary>
	<brief_title>Vaccine Therapy Plus QS21 Treating Patients With Progressive Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine optimal dose Thompson-Friedenreich [ TF ( c ) ] -keyhole limpet hemocyanin ( KLH ) conjugate plus adjuvant QS21 induces antibody response patient prostate cancer . II . Determine safety TF ( c ) -KLH conjugate prepare use MBS heterobifunctional linker plus QS21 . III . Assess postimmunization change prostate specific antigen level objective parameter disease patient . OUTLINE : This dose escalation study . Patients receive TF ( c ) -KLH conjugate adjuvant QS21 subcutaneously weekly 3 week , week 7 19 . Cohorts 5 patient receive escalate dos TF ( c ) -KLH vaccine optimal dose , base antibody response , reach . Patients follow monthly 6 month , every 3 month 1 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>QS 21</mesh_term>
	<mesh_term>Keyhole-limpet hemocyanin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven progressive prostate cancer primary therapy Radiographic change OR PSA least 1.0 ng/mL rise prostatectomy OR PSA least 2.0 ng/mL rise radiotherapy OR PSA rise 50 % intermittent hormonal therapy No metastatic disease radiography No active CNS epidural tumor Registered MSKCC9040 PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : At least 6 month Hematopoietic : WBC least 3500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 2.0 mg/dL OR SGOT le 3.0 time upper limit normal Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance least 40 mL/min Cardiovascular : No New York Heart Association class III/IV cardiac disease Pulmonary : No severe debilitate pulmonary disease Other : No active malignancy within 5 year except nonmelanomatous skin cancer No infection require antibiotic No narcotic dependent pain No positive stool guaiac exclude hemorrhoid No radiation induce proctitis No allergy seafood PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy recover No concurrent chemotherapy Endocrine therapy : See Disease Characteristics At least 2 week since change hormonal therapy ( except maintain castrate level testosterone ) , include prednisone dexamethasone At least 8 week since prior suramin and/or serum concentration suramin must less 50 micrograms/mL ( replacement hydrocortisone allow ) Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy recover No concurrent therapy measurable lesion Surgery : See Disease Characteristics No concurrent surgery</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>